Community-Acquired Pneumonia Treatment in Patients with Renal Impairment

Introduction to Treatment

The American Thoracic Society recommends a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) or a combination of a β-lactam plus a macrolide (with appropriate dose adjustments for renal impairment) for patients with community-acquired pneumonia (CAP) and impaired renal function with a GFR of 39 1, 2

Determine if the patient requires hospitalization or can be treated as an outpatient based on severity of illness, as recommended by the American Thoracic Society 1
For hospitalized non-ICU patients with CAP and renal impairment, the American Thoracic Society recommends levofloxacin 750 mg daily (with dose adjustment for renal impairment) or moxifloxacin 400 mg daily (no dose adjustment needed for renal impairment) as first-line options 1, 2
The American Thoracic Society also recommends a β-lactam plus a macrolide combination as a first-line option, with β-lactam options including ceftriaxone 1-2 g daily (no dose adjustment needed for GFR of 39) or ampicillin-sulbactam 1.5-3 g every 6 hours (with dose adjustment) 1, 2

The American Thoracic Society recommends dose reduction of levofloxacin to 500 mg every 48 hours or 750 mg every 72 hours for GFR <50 ml/min 1
The American Thoracic Society notes that moxifloxacin does not require dose adjustment in renal impairment, making it a good choice 1, 2
The Infectious Diseases Society of America recommends no dose adjustment for ceftriaxone in mild to moderate renal impairment 3

The recommended regimens provide coverage for the most common CAP pathogens, including Streptococcus pneumoniae, atypical pathogens, Haemophilus influenzae, and other common respiratory pathogens, as noted by the American Thoracic Society and the European Respiratory Society 1, 4
The European Respiratory Society recommends treatment duration not exceeding 8 days in a responding patient 4
The Infectious Diseases Society of America recommends a minimum of 3 days of therapy for hospitalized patients with suspected bacterial CAP, and switching from intravenous to oral therapy when the patient is hemodynamically stable, improving clinically, and able to take oral medications 3

The American Thoracic Society recommends monitoring clinical response, assessing renal function periodically during treatment, and considering earlier follow-up imaging in patients with impaired renal function to ensure resolution 1, 3

The Infectious Diseases Society of America recommends avoiding aminoglycosides as they can further worsen renal function in patients with already impaired kidney function 3
The American Thoracic Society notes that fluoroquinolones may have increased risk of tendinopathy, QT prolongation, and C. difficile infection, which should be considered in the risk-benefit assessment 1
The American Thoracic Society recommends selecting an agent from a different class for patients recently treated with antibiotics (within 3 months) to reduce the risk of resistance 1